Aubrey Rankin

All filings by Aubrey Rankin on record concern Revance Therapeutics, Inc. Between 23 July 2020 and 15 March 2022, the trades on record add up to 19 filings.

Both buying and selling appear: 1 purchase worth €383k, against 11 sales worth €7.3M. The net balance comes to €6.9M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 7 share grants.

On 17 March 2022 came the latest disclosure, a share grant for €20k in Revance Therapeutics, Inc. The latest purchase dates back some time: it was published 1,799 days ago, on 6 December 2021. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.